Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells

Cell Death and Disease

Volumn 3, Issue 1, 2012, Pages

  Kharaziha, P ^a   Rodriguez, P ^a   Li, Q ^a   Rundqvist, H ^a   Bjorklund A C ^a   Augsten, M ^a   Ullen A ^a   Egevad, L ^a   Wiklund, P ^a   Nilsson, S ^a   Kroemer, G ^b,c,d,e,f   Grander, D ^a   Panaretakis, T ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Institut Gustave Roussy   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

ABT737; Apoptosis; Autophagy; Prostate cancer; Sorafenib; Tyrosine kinase inhibitor

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN BAD; PROTEIN MCL 1; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN KINASE P60; PYRIDINE DERIVATIVE;

ARTICLE; CANCER CELL; CELL DEATH; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG RESISTANCE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; APOPTOSIS; CARCINOMA; CELL PROLIFERATION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHOSPHORYLATION; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZENESULFONATES; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PHOSPHORYLATION; PRIMARY CELL CULTURE; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS PP60(C-SRC); PYRIDINES; SIGNAL TRANSDUCTION;

EID: 84863169200     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.1     Document Type: Article

References (37)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512. (Pubitemid 39315317)
2. Robinson D, He F, Pretlow T, Kung HJ. A tyrosine kinase profile of prostate carcinoma. Proc Natl Acad Sci USA 1996; 93: 5958-5962. (Pubitemid 26190784)
3. George DJ. Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. Urology 2002; 60 (3 Suppl 1): 115-121; discussion 122.
4. Chang YM, Kung HJ, Evans CP. Nonreceptor tyrosine kinases in prostate cancer. Neoplasia 2007; 9: 90-100.
5. Gioeli D. Signal transduction in prostate cancer progression. Clin Sci (Lond) 2005; 108: 293-308. (Pubitemid 40516993)
6. Papatsoris AG, Karamouzis MV, Papavassiliou AG. The power and promise of 'rewiring' the mitogen-activated protein kinase network in prostate cancer therapeutics. Mol Cancer Ther 2007; 6: 811-819. (Pubitemid 46554551)
7. Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 2008; 16: 368-377.
8. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554. (Pubitemid 38541907)
9. Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007; 97: 678-685. (Pubitemid 47339893)
10. Yoshimoto M, Cutz JC, Nuin PA, Joshua AM, Bayani J, Evans AJ et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 2006; 169: 128-137. (Pubitemid 44287105)
11. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL et al. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001; 159: 431-437. (Pubitemid 32751073)
12. Urbich C, Knau A, Fichtlscherer S, Walter DH, Bruhl T, Potente M et al. FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells. FASEB J 2005; 19: 974-976. (Pubitemid 40827722)
13. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109. (Pubitemid 39331023)
14. Ullen A, Farnebo M, Thyrell L, Mahmoudi S, Kharaziha P, Lennartsson L et al. Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. Int J Oncol 2010; 37: 15-20.
15. Chi KN, Ellard SL, Hotte SJ, Czaykowski P, Moore M, Ruether JD et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 2008; 19: 746-751. (Pubitemid 351461047)
16. Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008; 14: 209-214. (Pubitemid 351377997)
17. Steinbild S, Mross K, Frost A, Morant R, Gillessen S, Dittrich C et al. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 2007; 97: 1480-1485. (Pubitemid 350175850)
18. Karlou M, Tzelepi V, Efstathiou E. Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol 2010; 7: 494-509.
19. Pietras K,Östman A. Hallmarks of cancer: Interactions with the tumor stroma. Exp Cell Res 2010; 316: 1324-1331.
20. Grander D, Panaretakis T. Autophagy: cancer therapy's friend or foe? Future Med Chem 2010; 2: 285-297.
21. Morselli E, Galluzzi L, Kepp O, Vicencio JM, Criollo A, Maiuri MC et al. Anti- and pro-tumor functions of autophagy. Biochem Biophys Acta 2009; 1793: 1524-1532.
22. Ding Q, Huo L, Yang JY, Xia W, Wei Y, Liao Y et al. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res 2008; 68: 6109-6117.
23. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009; 15: 68-74.
24. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-11858. (Pubitemid 46094197)
25. Datta SR, Katsov A, Hu L, Petros A, Fesik SW, Yaffe MB et al. 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Molecular Cell 2000; 6: 41-51.
26. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochem Biophys Acta 2007; 1773: 1263-1284. (Pubitemid 47125967)
27. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999; 286: 1741-1744. (Pubitemid 129515882)
28. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009; 6: 587-595.
29. Masuda M, Takano Y, Iki M, Asakura T, Hashiba T, Noguchi S et al. Prognostic significance of Ki-67, p53, and Bcl-2 expression in prostate cancer patients with lymph node metastases: a retrospective immunohistochemical analysis. Pathol Int 1998; 48: 41-46.
30. Bubendorf L, Sauter G, Moch H, Jordan P, Blochlinger A, Gasser TC et al. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 1996; 148: 1557-1565. (Pubitemid 26135896)
31. Pan J, Quintas-Cardama A, Manshouri T, Giles FJ, Lamb P, Tefferi A et al. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alphaexpressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia 2007; 21: 1395-1404. (Pubitemid 46965280)
32. Herrant M, Jacquel A, Marchetti S, Belhacene N, Colosetti P, Luciano F et al. Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 2004; 23: 7863-7873. (Pubitemid 39457036)
33. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000; 19: 5720-5728.
34. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002; 8: 2912-2923. (Pubitemid 35025739)
35. Castedo M, Ferri K, Roumier T, Metivier D, Zamzami N, Kroemer G. Quantitation of mitochondrial alterations associated with apoptosis. J Immunol Methods 2002; 265: 39-47. (Pubitemid 34628803)
36. Panaretakis T, Pokrovskaja K, Shoshan MC, Grander D. Activation of Bak, Bax, and BH3- only proteins in the apoptotic response to doxorubicin. J Biol Chem 2002; 277: 44317-44326. (Pubitemid 36157866)
37. Panaretakis T, Pokrovskaja K, Shoshan MC, Grander D. Interferon-alpha- induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax. Oncogene 2003; 22: 4543-4556. (Pubitemid 36920698)